89bio (ETNB) | Stock Overview & Key Data

$9.03

17.27%

| 89bio Stock Comparison:

89bio vs Vertex 89bio vs Regeneron 89bio vs Amicus Therapeutics 89bio vs Kymera Therapeutics 89bio vs Cg Oncology 89bio vs S&P 500 | Market

89bio Performance Comparison

Loading chart data...

89bio

Healthcare Sector

S&P 500

View Full Price History

Stock Range

Today's Range

Low: $7.51 High: $9.36

on May 20, 2025

52 Week Range

Low: $4.16 High: $11.84

on April 9, 2025

on February 5, 2025

All-Time High: $47.25 on March 2, 2020

Key Statistics

Market Cap i $1.5B

EPS i -3.46

P/E Ratio (TTM) i N/A

Forward P/E i -3.55

P/B Ratio i 2.45

PEG Ratio i -3.55

Div. Yield i 0.00%

ROE i -69.30%

Beta i 1.474

Debt to Equity i 6.21

Financial Highlights

Profitability

Gross Margin i N/A

Operating Margin i 0.00%

Profit Margin i 0.00%

Returns and Earnings

Return on Assets (TTM) i -39.93%

Return on Equity (TTM) i -69.30%

EBITDA i $-403.2M

Net Income (TTM) i $-386.7M

Growth

Revenue (TTM) i

Revenue Per Share (TTM) i

Quarterly Revenue Growth i N/A

Quarterly Earnings Growth i N/A

Peer Performance Comparison

Company	Market Cap	1W	1M	3M	6M	YTD	1Y	3Y	5Y
89bio ETNB	1.49B Small-cap	15.64%	43.86%	-17.70%	13.03%	13.03%	10.81%	201.67%	-64.98%
Vertex VRTX	114.83B Large-cap	3.50%	-6.37%	-6.92%	-0.91%	10.19%	-2.16%	63.33%	55.25%
Regeneron REGN	66.38B Large-cap	7.03%	9.44%	-11.71%	-17.33%	-14.08%	-37.60%	-11.28%	0.30%
Amicus Therapeutics FOLD	1.93B Small-cap	9.63%	-1.64%	-27.23%	-31.18%	-29.11%	-31.68%	-16.98%	-47.12%
Kymera Therapeutics KYMR	2.00B Small-cap	0.90%	15.68%	-16.03%	-28.67%	-23.16%	-7.75%	108.70%	-5.56%
Cg Oncology CGON	2.00B Small-cap	9.84%	30.13%	-5.88%	-17.62%	-8.32%	-18.53%	-23.92%	-23.92%

Ownership & Short Interest

Insider Ownership i 0.63%

Institutional Ownership i 108.82%

Shares Short i 17M

Short Ratio i 9.20

Short % of Shares Outstanding i 16.51%

Average 10-Day Volume i 2M

Average 90-Day Volume i 2M

89bio Recurring Investment / Dollar-Cost Averaging Calculator

Calculate how a regular investment in 89bio would have performed over time.

Investment Amount

Investment Frequency

Start Date

End Date (Optional)

If not specified, the latest available data will be used

Reinvest Dividends

Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.

Frequently Asked Questions

What is ETNB's 52-week high and low?

In the last 52 weeks, 89bio reached a high of $11.84 (on February 5, 2025) and a low of $4.16 (on April 9, 2025).

What is the market cap and P/E ratio for ETNB?

Curious about 89bio's size and valuation? Its market capitalization stands at 1.49B. When it comes to valuation, the P/E ratio (trailing twelve months) is N/A, and the forward P/E (looking ahead) is -3.55.

Does ETNB pay dividends? If so, what's the yield?

As for dividends, 89bio isn't currently offering a significant yield, or that specific data isn't available right now. Its payout ratio, which shows how much of its earnings are paid as dividends, is 0.00%.

Who are 89bio's main competitors or similar companies to consider before investing?

When looking at 89bio, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:

Company	Mkt Cap	Sector	Industry	1Y Return	3Y Return
Vertex VRTX	114.83B	Healthcare	Biotechnology	-2.16%	63.33%
Regeneron REGN	66.38B	Healthcare	Biotechnology	-37.60%	-11.28%
Amicus Therapeutics FOLD	1.93B	Healthcare	Biotechnology	-31.68%	-16.98%
Kymera Therapeutics KYMR	2.00B	Healthcare	Biotechnology	-7.75%	108.70%
Cg Oncology CGON	2.00B	Healthcare	Biotechnology	-18.53%	-23.92%

For a more comprehensive list, please see the Peer Performance Comparison table on this page.

What are the key financial health indicators for 89bio Inc.? (e.g., ROE, Debt/Equity)

To get a sense of 89bio's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -69.30%, the Debt to Equity ratio from the most recent quarter is 6.21, and its Gross Profit Margin stands at N/A.

What is the recent revenue and earnings growth for ETNB?

Looking at 89bio's growth, its revenue over the trailing twelve months (TTM) was $0. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.

How much of ETNB stock is held by insiders and institutions?

Wondering who owns 89bio stock? Company insiders (like executives and directors) hold about 0.63% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 108.82%.

For more common questions about our data, please visit our About Data page.

Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.